Veracyte Acquires Convergent Genomics
By Katherine HamiltonVeracyte acquired Convergent Genomics, a bladder cancer treatment company, in a deal worth up to $180 million.The cancer diagnostics company said Monday that the deal will add Convergent's proprietary urinary tumor DNA technology to its product portfolio.The deal includes $150…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.